UY35293A - Isotiazoles sustituidos con amino - Google Patents

Isotiazoles sustituidos con amino

Info

Publication number
UY35293A
UY35293A UY0001035293A UY35293A UY35293A UY 35293 A UY35293 A UY 35293A UY 0001035293 A UY0001035293 A UY 0001035293A UY 35293 A UY35293 A UY 35293A UY 35293 A UY35293 A UY 35293A
Authority
UY
Uruguay
Prior art keywords
amino
isotiazoles
replaced
compositions
useful
Prior art date
Application number
UY0001035293A
Other languages
English (en)
Inventor
Dr Lars Bärfacker
Dr Jens Ackerstaff
Dr Gerhard Siemeister
Dr Detlef Stöckigt
Dr Philip Lienau
Dr Stefan Prechtl
Dr Benjamin Bader
Sr Antje Margret Wengner
Dr Katrin Nowak-Reppel
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of UY35293A publication Critical patent/UY35293A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Isotiazoles sustituidos con amino de la fórmula general (I) S N R 1 N O H R 2 N H A (I), donde A, R1 y R2 son como se los define en las reivindicaciones. Métodos para elaborarlos. Compuestos intermediarios útiles su elaboración. Compos iciones y combinaciones farmacéuticas que los com prenden. Su uso en la manufactura de composicione s farmacéuticas útiles en la profilaxis o el trat amiento de diversas enfermedades, particularmente de los neoplasmas, en forma de agentes individua les o en combinación con otros ingredientes activ os.
UY0001035293A 2013-01-30 2014-01-30 Isotiazoles sustituidos con amino UY35293A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13153278 2013-01-30

Publications (1)

Publication Number Publication Date
UY35293A true UY35293A (es) 2014-08-29

Family

ID=47623964

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035293A UY35293A (es) 2013-01-30 2014-01-30 Isotiazoles sustituidos con amino

Country Status (10)

Country Link
US (1) US9682995B2 (es)
EP (1) EP2951174B1 (es)
JP (1) JP2016506921A (es)
CN (1) CN104936956A (es)
CA (1) CA2899399A1 (es)
ES (1) ES2634014T3 (es)
HK (1) HK1215250A1 (es)
TW (1) TW201444833A (es)
UY (1) UY35293A (es)
WO (1) WO2014118186A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160046604A1 (en) * 2013-03-21 2016-02-18 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
HRP20191283T1 (hr) 2014-01-24 2019-10-18 Turning Point Therapeutics, Inc. Diaril makrocikli kao modulatori protein kinaze
WO2015113927A1 (en) * 2014-01-29 2015-08-06 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
WO2015113920A1 (en) * 2014-01-29 2015-08-06 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
EP2980088A1 (en) * 2014-07-28 2016-02-03 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
EP2977376A1 (en) * 2014-07-25 2016-01-27 Bayer Pharma Aktiengesellschaft Amino-substituted isoxazoles
EP2977377A1 (en) * 2014-07-25 2016-01-27 Bayer Pharma Aktiengesellschaft Amino-substituted isoxazoles
EP2977375A1 (en) * 2014-07-25 2016-01-27 Bayer Pharma Aktiengesellschaft Amino-substituted isoxazoles
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
EP4397665A3 (en) 2015-07-06 2024-08-21 Turning Point Therapeutics, Inc. Diaryl macrocycle polymorph
CN108358864B (zh) * 2017-12-15 2020-07-17 五邑大学 一种2-酰基-5-苯基噁唑类微管蛋白抑制剂的制备方法及应用
CN108467392B (zh) * 2018-03-30 2022-01-21 广西师范大学 2-(ω-二烷基氨)胺烷基-3-芳基并唑类喹喔啉化合物及其制备方法和应用
BR112022006791A2 (pt) 2019-10-09 2022-06-28 Bayer Ag Novos compostos heteroaril-triazol como pesticidas
JPWO2021132577A1 (es) * 2019-12-27 2021-07-01
CN119499241A (zh) * 2021-08-24 2025-02-25 西北农林科技大学 噻唑羧酰胺类化合物的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US7105682B2 (en) * 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
GB0215775D0 (en) 2002-07-06 2002-08-14 Astex Technology Ltd Pharmaceutical compounds
EP1845973B1 (en) * 2005-01-21 2015-08-12 Astex Therapeutics Limited Pharmaceutical compounds
JP4388997B2 (ja) 2006-09-05 2009-12-24 協和発酵キリン株式会社 イミダゾール誘導体
JP5103604B2 (ja) * 2006-10-31 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼ阻害剤としての２−アミノチアゾール−４−カルボン酸アミド
US8084454B2 (en) * 2007-04-11 2011-12-27 Canbas Co., Ltd. Compounds with anti-cancer activity
ES2452349T3 (es) 2007-05-21 2014-04-01 Novartis Ag Inhibidores de CSF-1R, composiciones, y métodos de uso
MX2010006882A (es) 2007-12-25 2010-10-05 Kissei Pharmaceutical Derivado novedoso de catecol, composición farmaceutica que contiene el mismo, uso del derivado de catecol, y uso de la composición farmaceutica.
AU2009204483B2 (en) * 2008-01-04 2014-03-13 Intellikine, Llc Certain chemical entities, compositions and methods
US8716280B2 (en) 2009-01-21 2014-05-06 Basilea Pharmaceutica Ag Bicyclic antibiotics
WO2011003793A1 (en) 2009-07-06 2011-01-13 Basf Se Pyridazine compounds for controlling invertebrate pests
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2651950A1 (en) 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012085857A1 (en) 2010-12-22 2012-06-28 Actelion Pharmaceuticals Ltd 3,8-diaza-bicyclo[4.2.0]oct-3-yl amides

Also Published As

Publication number Publication date
ES2634014T3 (es) 2017-09-26
US9682995B2 (en) 2017-06-20
CN104936956A (zh) 2015-09-23
TW201444833A (zh) 2014-12-01
US20150368260A1 (en) 2015-12-24
WO2014118186A1 (en) 2014-08-07
JP2016506921A (ja) 2016-03-07
HK1215250A1 (zh) 2016-08-19
EP2951174B1 (en) 2017-04-26
CA2899399A1 (en) 2014-08-07
EP2951174A1 (en) 2015-12-09

Similar Documents

Publication Publication Date Title
UY35293A (es) Isotiazoles sustituidos con amino
DOP2016000208A (es) Benzimidazol-2-aminas como inhibidores de midh1
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2017001035A2 (es) “2-(morfolin-4-il)-1,7-naftiridinas sustituidas, composiciones y combinaciones farmacéuticas que las comprenden, y compuestos intermediarios
UY37461A (es) 1,2,4 – triazolonas 2,4,5 trisustituida
CR20140113A (es) Imidazopiridazinas sustituidas con amino
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
PE20151759A1 (es) Imidazopiridazinas sustituidas
NI201700078A (es) Pirazolpiridinaminas
CR20160016A (es) Pirazolpiridinas sustituidas
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CO2020003475A2 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
DOP2016000268A (es) Compuestos de azol amido–sustituidos como inhibidores de tnks1 y/o tnks2
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
UY36983A (es) Pirazolopiridinaminas sustituidas
UY34630A (es) Imidazopiridazinas sustituidas con amino
UY37032A (es) Compuestos de heteroarilbenzimidazol

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211029